We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > LGS

News List

Takeda secures global rights to develop and commercialise soticlestat pharmaceutical-business-review
March 09, 2021
Takeda Pharmaceutical Company has entered into an exclusive agreement to secure global rights from Ovid Therapeutics to develop and commercialise the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic ...
Aquestive Therapeutics Launches Sympazan americanpharmaceuticalreview
December 03, 2018
Aquestive Therapeutics has launched Sympazan (clobazam) oral film with availability nationwide through retail pharmacies and mail order.....
NEJM publishes second successful Epidiolex trial in LGS pharmatimes
July 12, 2018
The New England Journal of Medicine has published the second of two late stage studies showing that GW Pharma’s cannabinoid Epidiolex cut seizures in patients with the rare childhood epilepsy Lennox-Gastaut Syndrome.
NEJM publishes second successful Epidiolex trial in LGS pharmatimes
May 24, 2018
In the trial - the first dose-ranging study to compare cannabidiol to placebo as add-on therapy in LGS - both doses of Epidiolex significantly reduced drop seizure frequency in patients with poor seizure control despite the use of multiple anti-epileptic